Introduction

Axillary lymph node dissection has been the traditional standard of care for breast cancer patients with nodal metastases (1-3). Nodal metastases are very rarely diagnosed clinically and are generally identified by axillary ultrasound with fine needle aspiration cytology or core biopsy of the suspicious axillary lymph nodes (4-6). For patients with normal axillary ultrasound, sentinel lymph node biopsy (SNB) is performed to confirm nodal metastases.

Once nodal metastases are identified either via axillary ultrasound or SNB, axillary lymph node dissection is performed to achieve local disease control (7, 8). This technique also provides accurate nodal status to inform the decision to provide radiotherapy to the supraclavicular region and influences decisions on administering systemic therapy (9, 10).

An increased understanding of tumour biology in recent years has suggested that other patient- and tumour-related factors should also influence the decision to treat patients with systemic therapy (11, 12). In addition, early cancer detection by screening mammograms leads to early management and reduced tumour nodal involvement (13, 14). Also in certain patients, adjuvant systemic treatment is needed despite no lymph nodal involvement (15). These concepts in addition to the fact that axillary lymph node dissection is associated with unacceptable risks of complications (16-18) (seroma, infection, paraesthesia, shoulder pain, weakness and lymphedema) has raised
Validation of Memorial Sloan Kettering Cancer Center nomogram to detect non-sentinel lymph node metastases in a United Kingdom cohort

questions as to the need for complete axillary lymph node dissection in all patients with positive sentinel node biopsies (19).

A variety of approaches have evolved in recent years to identify groups of low-risk patients who could safely avoid axillary lymph node dissection. The American College of Surgeons Oncology Group (ACOSOG) demonstrated in the Z0011 trial that certain groups of patients can safely avoid lymph node dissection without affecting local control or survival (20, 21). These groups of patients have early stage breast cancer with tumour sizes less than 5 cm and have undergone lumpectomy with sentinel biopsy. If they have clear margins and one or two positive nodes without extra nodal extension or matting, they could forego axillary lymph node dissection provided they are treated with whole breast radiation postoperatively. Although it was considered as a practice changing trial, the selection bias, difficulty in applying this treatment to younger patients and those with invasive lobular disease and the use of tangential field radiation associated with the trial, limits the true clinical significance of these findings (18-20). Systemic review and meta-analysis by Ram et al. (22) was unable to conclude favourably to avoid completion axillary node dissection on sentinel node macrometastases. There is currently a trial (23) in the United Kingdom, recruiting patients to identify subgroup of patients with 1 or 2 nodal metastases who could avoid axillary dissection.

Different prediction models have also been published to identify the risk of non-sentinel lymph node metastases (24). If patients have a low score, suggesting that they are unlikely to have non-sentinel node metastases, axillary lymph node dissection is avoided. A review of these models indicated that the Memorial Sloan Kettering Cancer Center (MSKCC) model (25) is robust despite some limitations (26, 27). This model was validated by a total of 373 cases and the area under the receiver-operating characteristic curve (AUC) was 0.77, which proved to have a good diagnostic value.

The primary aim of our study was to apply the tumour characteristics in the MSKCC nomogram and assess the risk prediction of non-sentinel node metastases in a United Kingdom cohort. We also analysed the clinical and pathological outcomes of breast cancer patients who underwent axillary lymph node dissection after positive SNB.

Patients and methods

All breast cancer patients who underwent SNB after meeting the criteria (histologically proven breast cancer, negative axillary lymph nodes on palpation and sonography) were included in the study from the surgical database of Southend University Hospital.

For SNB, we used either blue dye technique or the combined technique using radio-isotope. Both techniques have been described elsewhere in detail (28). For blue dye technique, Patent Blue V was injected subdermally in the periareolar region in the upper outer quadrant of the cancerous breast prior to surgery. For combined technique, 99mTc-nanocol was injected at the same place 3 to 5 minutes prior to the injection of blue dye. Intraoperatively, the sentinel lymph nodes (SLN) were detected by the appearance of blue node in the former procedure and the signal is detected (hot) using a hand-held gamma probe along with blue node in the latter procedure and sent for pathological evaluation by haematoxylin–eosin staining (H&E) and immunohistochemistry (IHC).

Sentinel node is considered negative even if there are isolated tumour cells and/or micro metastases (less than 2mm in size) and considered positive if they are more than 2mm in size by standard nodal assessment or if there are any extra capsular spread on micro metastasis. Patients with positive sentinel lymph node biopsies were discussed in the multi-disciplinary meeting and offered level II and/or level III axillary dissection provided no significant medical comorbidities were noted. Details regarding positive SNB and further axillary lymph node dissection were obtained from histopathological reports. Demographics and tumour characteristics were identified from multi-disciplinary discussions. Clinical letters were used to identify the follow-up of these patients, including any significant events.

All analyses were conducted with The Graph Pad software (Prism version 5). For numeric data, values are expressed in median with percentages. Numeric data were analysed with Student’s-t-test if normal distribution and categoric data, with the Chi-Square-test or with Fisher’s exact test.

The MSKCC nomogram is a validated model to estimate the predictive value of the involvement of additional non-sentinel lymph node metastases. The nomogram is accessed at http://nomograms.mskcc.org/Breast/BreastAdditionalNonSLNMetastasesPage.a
spx. Nine independent variables, including whether frozen sectioning was performed, pathological size, tumour type and grade, number of positive and negative sentinel nodes, method of node detection, lymphovascular invasion, multifocality and oestrogen receptors status were uploaded into the MSKCC online calculator.

Prediction scores were obtained and tabulated to construct the ROC curves, and the AUC was calculated. Further information on the methods of development and internal validation are available on the above internet site and the corresponding publication (25).

The value of the AUC is between 0.5 and 1.0. The AUC has a lower accuracy at 0.5 to 0.7 and a superior accuracy in the range of 0.7 to 0.9; the AUC has high accuracy at values greater than 0.9.

**Results**

Of the 1745 patients who received surgery for breast cancer from April 2009 to March 2015, 1470 patients had sentinel lymph node biopsies. 117 patients had a positive sentinel node biopsy, with a positivity rate of 8%. Three patients were excluded as two patients had neo adjuvant chemotherapy before axillary lymph node dissection and one patient declined surgery. The remaining 114 patients were considered eligible for the study.

**Pathological factors of sentinel node metastases**

The overall descriptive clinical and histopathological characteristics of patients with positive SLN biopsy (n = 114) are shown in Table 1. The mean and median ages were 59.5 and 61 years respectively (ranging 24 - 85). The mean and median tumour sizes were 20.6 and 21 mm respectively, ranging from 1 to 4.5 cm. Most of the tumours were invasive ductal carcinomas (93%) and of higher grades (Grade II, 53%; instead of Grade III, 48%).

Tumours in 51 patients (44.7%) were associated with lymphovascular invasion, and 107 (93.8%) tumours were oestrogen positive. Tumours were progesterone positive in 84 patients (73.7%), and Her2 was overexpressed in 11.4% of patients. Most patients had wide local excision (78.9%), radiotherapy (86.8%) and hormonal treatment (96.5%). Letrozole (65.5%) was the more frequently prescribed hormonal therapy, and more than half of the patients received chemotherapy (61.4%).

**Table 1 - PATIENT AND TUMOUR CHARACTERISTICS OF PATIENTS WHO UNDERWENT AXILLARY LYMPH NODE DISSECTION (ALND) AFTER POSITIVE SENTINEL NODE BIOPSY.**

| Age (year) | Median (range) |
|------------|----------------|
| < 50       | 21             |
| > 50       | 93             |

| Tumour size | Median (range) |
|-------------|----------------|
| T1 (≤ 20 mm)| 45             |
| T2 (20-50 mm)| 69         |

| Tumour type |
|-------------|
| Ductal cancer | 93 |
| Lobular cancer | 11 |
| Tubular cancer | 4 |
| Mixed | 6 |

| Grade |
|-------|
| Grade I | 13 |
| Grade II | 53 |
| Grade III | 48 |

| Tumour subtype |
|----------------|
| ER positive/Her2 negative | 94 |
| Triple negative | 5 |
| Her2 positive | 13 |

| Receptor status |
|-----------------|
| ER positive | 107 |
| ER negative | 7 |
| PR positive | 84 |
| PR negative | 30 |

| Lymphovascular invasion |
|-------------------------|
| Present | 51 |
| Absent | 63 |

| Surgical management |
|---------------------|
| Wide local excision | 90 |
| Mastectomy | 24 |

| N stage after ALND |
|---------------------|
| N1 (1-3 nodes) | 87 |
| N2 (4-9 nodes) | 25 |
| N3 (≥10 nodes) | 2 |

| Radiotherapy |
|--------------|
| 99 |

| Chemo therapy |
|---------------|
| 70 |

| Hormonal Treatment |
|--------------------|
| Letrozole | 72 |
| Tamoxifen | 23 |
| Switch therapy | 12 |
| Other aromatase inhibitor | 3 |
| No treatment | 4 |
Validation of Memorial Sloan Kettering Cancer Center nomogram to detect non-sentinel lymph node metastases in a United Kingdom cohort

Most of the patients had N1 disease (87 patients, 76.3%). The median number of positive nodes detected for patients with N1 disease was 1 and 4 for those with N2 disease. The average number of nodes obtained from the sentinel lymph node biopsy was 4.3. The median number of total axillary lymph nodes identified from axillary lymph node dissection was 12 (range from 10 to 23).

**Nomogram**

The AUC-ROC achieved by the MSKCC nomogram when predicting the risk of non-SLN metastases was 0.5304 (Figure 1) with a 95% confidence interval of 0.3527 to 0.7080. This result was not statistically significant (p value = 0.7303).

In conclusion, the MSKCC nomogram does not provide an accurate prediction of the probability of non-SLN metastasis in our cohort of SLN-positive breast cancer patients.

**Survival**

At a median follow-up of 37 months (range from 9 to 65 months), four significant events were noted. One patient died during adjuvant chemotherapy, another patient died of lung metastasis 28 months after the initial treatment. Third patient died of generalised illness with no proven metastasis, and fourth patient developed contralateral breast cancer 51 months after the initial treatment. Overall there was no axillary recurrences. The disease free survival was 86.4% and overall survival rate was 88.4%.

**Non-sentinel lymph node metastasis**

A total of 38 patients of the 1470 patients (2.6%) showed non-SLN metastasis. The prevalence of non-SLN metastasis in the group of SLN positive patients was 33.3% (38 of 114 patients), with a mean number of 2.87 involved lymph nodes.

Comparing the histopathological factors by presence or absence of further non-SLN metastases as in Table 2, only tumour size (p< 0.01) correlated significantly with non-SLN metastasis. Tumour grade, histology, lymphovascular infiltration, type of surgery and biologic features (oestrogen and progesterone receptor status, Her2/neu expression) of the primary tumour did not correlate with the prevalence of non-SLN metastasis.

**Discussion and conclusions**

Sentinel lymph node biopsy has become widely accepted as the preferred method for staging node-negative breast cancer (16, 29, 30) while axillary
lymph node dissection is recommended in patients with a positive sentinel node biopsy. However, with the changing trend in breast cancer surgery towards conservative approach, axillary lymph node dissection is considered by many studies as overtreatment. This is partly because only 50% of the patients with metastatic disease have further axillary metastases (31), as shown in our study where only 43.3% of the

![Table 2 - Comparison of histopathological factors by presence or absence of further non-sentinel lymph node metastases.](image)

| Patient characteristics       | ANC 0, Positive Lymph Nodes (n=76) | ANC 1 + Positive Lymph Nodes (n=38) | p value |
|------------------------------|-----------------------------------|------------------------------------|---------|
| **Age**                      |                                   |                                    |         |
| Median (Range)               | 61 (24-85)                        | 62 (35-83)                         |         |
| < 50 years                   | 14 (18.4%)                        | 5 (13.2%)                          | 0.11    |
| 50-69 years                  | 49 (64.5%)                        | 20 (52.6%)                         |         |
| ≥ 70 years                   | 13 (17.1%)                        | 13 (34.2%)                         |         |
| **Type of surgery**          |                                   |                                    |         |
| Breast Conserving            | 59 (77.6%)                        | 29 (76.3%)                         | 1       |
| Mastectomy                   | 17 (22.4%)                        | 9 (23.7%)                          |         |
| **Tumour size in mm**        |                                   |                                    |         |
| Median (Range)               | 21 (4-70)                         | 23 (12-75)                         | 0.01    |
| <20 mm                       | 34 (44.7%)                        | 11 (28.9%)                         |         |
| 20-30 mm                     | 29 (38.2%)                        | 19 (50%)                           |         |
| >30 mm                       | 13 (17.1%)                        | 8 (21.1%)                          |         |
| **MGR5 (NACH)**              |                                   |                                    |         |
| **Morphology of tumour**     |                                   |                                    |         |
| Ductal carcinoma             | 62 (81.6%)                        | 30 (78.9%)                         | 0.62    |
| Lobular Carcinoma            | 6 (7.9%)                          | 5 (13.2%)                          |         |
| Other types                  | 8 (10.5%)                         | 3 (7.9%)                           |         |
| **Tumour Grade**             |                                   |                                    |         |
| Grade 1                      | 11 (14.5%)                        | 2 (5.3%)                           | 0.23    |
| Grade 2                      | 32 (42.1%)                        | 21 (55.2%)                         |         |
| Grade 3                      | 33 (43.4%)                        | 15 (39.5%)                         |         |
| **ER status**                |                                   |                                    |         |
| Negative                     | 6 (7.9%)                          | 1 (2.6%)                           | 0.42    |
| Positive                     | 70 (92.1%)                        | 37 (97.4%)                         |         |
| **PR status**                |                                   |                                    |         |
| Negative                     | 21 (27.6%)                        | 9 (23.7%)                          | 0.82    |
| Positive                     | 55 (72.4%)                        | 29 (76.3%)                         |         |
| **Her2 Status**              |                                   |                                    |         |
| Negative                     | 68 (89.5%)                        | 33 (86.8%)                         | 0.75    |
| Positive                     | 8 (10.5%)                         | 5 (13.2%)                          |         |
| **Triple Negative**          |                                   |                                    |         |
| No                           | 72 (94.7%)                        | 37 (97.4%)                         | 0.66    |
| Yes                          | 4 (5.3%)                          | 1 (2.6%)                           |         |
| **Multifocality**            |                                   |                                    |         |
| No                           | 72 (94.7%)                        | 37 (97.4%)                         | 0.66    |
| Yes                          | 4 (5.3%)                          | 1 (2.6%)                           |         |
| **Lymphovascular Invasion**  |                                   |                                    |         |
| No                           | 45 (59.2%)                        | 18 (47.4%)                         | 0.23    |
| Yes                          | 31 (40.8%)                        | 20 (52.6%)                         |         |

A. Syed et al.
patients do have additional lymph nodal metastases. Therefore completion axillary lymph node dissection serves no therapeutic purpose in the remainder of the patients and more importantly cause significant morbidities (17, 18).

To overcome this tendency to over-treat, various tools have been identified to predict the risk of additional positive axillary nodes (non-sentinel) after positive SNB. If the risk prediction score is low (less than 10%), patients can safely avoid axillary lymph node dissection. The risk of non-sentinel metastases correlates with the size of the primary tumour, size of the metastases, number of sentinel nodes involved, lymphovascular invasion and extra nodal tumour extension (32, 33). These prognostic characteristics are incorporated in the prediction models to predict the risk of non-sentinel metastases. Of those prediction models, the MSKCC model is one of the more valid nomograms in various populations. Hence, we applied our data to this model to identify the risk of additional nodal involvement by drawing the ROC curve and calculating the AUC. The value of the AUC in our study was 0.530, which indicates lower accuracy in predicting the involvement of additional lymph nodes.

Literature review depicts the validation results from different studies were heterogeneous with more accuracy obtained in American and Australian studies and mixed results in European studies. Van Zee et al. (n=373) (25), from MSKCC obtained the ROC of 0.76, Degnim et al. (n= 89) (34) and Cripe et al. (n=92) (35) in USA obtained 0.86 and Soni et al. from Australia (n=149) (36) achieved a ROC of 0.75. However German based study by Klar et al. (n=98) (37) achieved only 0.58 and Pal et al. (n=118) (38) from UK obtained 0.68. These low prediction score in European studies is similar to our ROC of 0.53 (n=114) which questions the recommendation of MSKCC as a worldwide prediction model. It also highlights that there are some important contributing factors other than simple geographical location for lack of reproducibility of the MSKCC model.

Firstly, method of pathological assessment of sentinel nodes varies with different studies. MSKCC model uses frozen section as method of detection of metastases whilst other American and Australian studies use imprint cytology as methods of detection. These methods could possibly identify the isolated tumour cells or micrometastases as nodal metastases compared to the Haematoxylin and Eosin preparation which accurately classify them. This could explain the low prediction score in European studies which do not use intraoperative frozen section or imprint cytology as a marker for metastases.

Secondly, the size of the nodal metastases is not a feature of MSKCC model. Pal et al. in his revised Cambridge model obtained the higher accuracy score of 0.84 (from MSKCC score of 0.68) adding the criteria of the size of nodal metastases. It would be therefore appropriate to include the size as one of the parameter to obtain better accuracy among different populations.

In conclusion, it is important to identify the low risk group of breast cancer patients with nodal metastases who are at a low risk of additional non-sentinel metastases (39).

However to date there are no studies or models which were able to define this group reliably although Z0011 trial looks promising to redefine the axillary management of certain group of patients.

References

1. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, Renne G. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. New England Journal of Medicine. 2003 Aug 7;349(6):546-53.

2. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jallow LC, Frazier TG. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. The lancet oncology. 2010 Oct 31;11(10):927-33.

3. Lyman GH, Giuliano AE, Somerfield MR, Benson III AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody III HS, Edge SB, Galper S, Hayman JA. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. Journal of clinical oncology. 2005 Oct 20;23(30):7703-20.

4. Mainiero MB. Regional lymph node staging in breast cancer: the increasing role of imaging and ultrasound-guided axillary lymph node fine needle aspiration. Radiologic Clinics of North America. 2010 Sep 30;48(5):989-97.

5. Houssami N, Ciato S, Turner RM, Cody III HS, Macaskill P. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg. 2011 Aug;254(2):243-51. doi: 10.1097/SLA.0b013e31821f1564.

6. Coole-Lartigue J, Meterissian S. Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: a review. World Journal of Surgery. 2012 Jan;36(1):46-54.

7. Sosa JA, Diener-West M, Gusey Y, Chotti MA, Lange JR, Dooley WC, Zeiger MA. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Annals of surgical oncology. 1998 Mar 1;5(2):140-9.

8. Cabanes PA, Salmon RJ, Viloq J, Durand JC, Fournet A, Gautier C, Asselain B, Curie Tl. Value of axillary dissection for the identification of sentinel nodes.
in addition to lumpectomy and radiotherapy in early breast cancer. The Lancet. 1992 May 23;339(8784):1245-8.

9. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Journal of the National Cancer Institute. 1998 Nov 4;90(21):1601-8.

10. Abrams JS. Adjuvant therapy for breast cancer - results from the USA consensus conference. Breast Cancer. 2001 Oct 1;8(4):298-304.

11. Van De Vijver MJ, He YD, Van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M. A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine. 2002 Dec 19;347(25):1999-2009.

12. Albinus KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bagurani R, Bachner FL, Davidson NE. Sledge GW. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The lancet oncology. 2010 Jan 31;11(1):55-65.

13. Spillane AJ, Kennedy CW, Gillett DJ, Carmalt HL, Janu NC, Rickard MT, Donnellan MJ. Screen-detected breast cancer compared to symptomatic presentation: An analysis of surgical treatment and end-points of effective mammographic screening. ANZ journal of surgery. 2001 Jul 16;71(7):398-402.

14. Chen TH, Jonsson SH, Lenner P. Effect of mammographic service screening on stage at presentation of breast cancers in Sweden. Cancer. 2007 Jun 1;109(11):2205-12.

15. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Bachner FL, Watson D, Bryant J, Costantino JP. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of clinical oncology. 2006 Aug 10;24(23):3726-34.

16. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixom JM, Yangou C, Horgan K, Bundred N, Monypenny I, England D. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. Journal of the National Cancer Institute. 2006 May 3;98(9):599-609.

17. Goyal A, Newcombe RG, Chhabra A, Mansel RE. Morbidity in breast cancer patients with sentinel node metastases under-going delayed axillary lymph node dissection (ALND) compared with immediate ALND. Annals of surgical oncology. 2008 Jan 1;15(1):262-7.

18. Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, Skelly JM, Harlow SP, Weaver DL, Mammouss EP, Costantino JP. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. Journal of surgical oncology. 2010 Aug 1;102(2):111-8.

19. Rutgers EJ. Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases. Journal of Clinical Oncology. 2008 Feb 10;26(5):698-702.

20. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitchow PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama. 2011 Feb 9;305(6):569-75.

21. Giuliano AE, McCall L, Beitsch P, Whitchow PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Annals of surgery. 2010 Sep 1;252(3):426-33.

22. Ram R, Singh J, McCaig E. Sentinel node biopsy alone versus completion axillary node dissection in node positive breast cancer: systematic review and meta-analysis. International journal of breast cancer. 2014 Oct 14:2014.

23. Goyal A, Coleman RE, Dodwell DJ, Fallowfield L, Jenkins VA, Mann B, Reed MW, POSNOC Trialists Group. POSNOC: Positive sentinel node - Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy: A randomised trial looking at axillary treatment in early breast cancer (ISRCTN54765244).

24. Coutant C, Morel O, Antoine M, Uzan S, Barranger E. Is axillary lymph node dissection always necessary in breast cancer patients with a positive sentinel node?. Journal de chirurgie. 2007;144(6):492-501.

25. Van Zee KJ, Maisseus DM, Bevilacqua JL, Booolbol SK, Fey JV, Tan LK, Borgen PI, Cody HS, Kattan MW. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Annals of surgical oncology. 2003 Nov 1;10(10):1140-51.

26. Ural B, Gur AS, Kayiran O, Johnson R, Ahrendt G, Bonaventura M, Soran A. Models for predicting non-sentinel lymph node positivity in sentinel node positive breast cancer: the importance of scoring system. International journal of clinical practice. 2008 Nov 1;62(11):1785-91.

27. Hessman CJ, Naik AM, Kearney NM, Jensen AJ, Diggs BS, Troxell ML, Vetto JT. Comparative Validation of Online Nomograms for Predicting Nonsentinel Lymph Node Status in Sentinel Lymph Node—Positive Breast Cancer. Archives of surgery. 2011 Sep 19;146(9):1035-40.

28. Varghese P, Mostafa A, Abdel-Rahman AT, Akberali S, Gattuso J, Canizales A, Wells CA, Carpenter R. Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localisation in early breast cancer. European Journal of Surgical Oncology (EJSO). 2007 Mar 31;33(2):147-52.

29. Giuliano AE, Kirgan DM, Guenster JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Annals of surgery. 1994 Sep;220(3):391.

30. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Annals of surgery. 1995 Sep;222(3):394.

31. Reynolds C, Mick R, Donehue JH, Grant CS, Farley DR, Callans LS, Orel SG, Keeney GL, Lawton TJ, Czernecki BJ. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? Journal of Clinical Oncology. 1999 Jun;17(6):1720-26.

32. Kamath VJ, Giuliano R, Dawaw EL, Cantor A, Berman C, Hu NN, Cox CE, Reingten DS. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Archives of surgery. 2001 Jun 1;136(6):688-92.

33. Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC, Giuliano AE. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000 Aug 1;89(3):574-81.

34. Degnim AC, Reynolds C, Pantvaidya G, Zakaria S, Hoskin T, Barnes S, Roberts MV, Lucas PC, Oh K, Koker M, Sabel MS. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. The American Journal of Surgery. 2005 Oct 31;190(4):543-50.

35. Cripe MH, Beran LC, Liang WC, Sickle-Santanello BJ, The
Validation of Memorial Sloan Kettering Cancer Center nomogram to detect non-sentinel lymph node metastases in a United Kingdom cohort

likelihood of additional nodal disease following a positive sentinel lymph node biopsy in breast cancer patients: validation of a nomogram. The American Journal of Surgery. 2006 Oct 31;192(4):484-7.
36. Soni NK, Carmalt HL, Gillett DJ, Spillane AJ. Evaluation of a breast cancer nomogram for prediction of non-sentinel lymph node positivity. European Journal of Surgical Oncology (EJSO). 2005 Nov 30;31(9):958-64.
37. Klar M, Jochmann A, Foeldi M, Stumpf M, Gitsch G, Stickeler E, Watermann D. The MSKCC nomogram for prediction the likelihood of non-sentinel node involvement in a German breast cancer population. Breast Cancer Research and Treatment. 2008 Dec 1;112(3):523-31.
38. Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. The British Journal of Surgery. 2008 Mar;95(3):302-9.
39. Atalay C. New concepts in axillary management of breast cancer. World Journal of Clinical Oncology. 2014 Dec 10;5(5):895.